Fate Therapeutics' (FATE) CEO Scott Wolchko on Q1 2018 Results - Earnings Call Transcript [Seeking Alpha]
Fate Therapeutics, Inc. (FATE)
Last fate therapeutics, inc. earnings: 3/2 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.fatetherapeutics.com/investor-relations
Company Research
Source: Seeking Alpha
Fate Therapeutics, Inc. (NASDAQ: FATE ) Q1 2018 Results Earnings Conference Call May 10, 2018 5:00 PM ET Executives Scott Wolchko - President and CEO Chris Storgard - Chief Medical Officer Dan Shoemaker - Chief Scientific Officer Analysts Edward Tenthoff - Piper Jaffray David Nierengarten - Wedbush Securities Do Kim - BMO Capital Markets Operator Welcome to Fate Therapeutics First Quarter 2018 Financial Results Conference Call. At this time all participants are in a listen-only mode. This call is being webcast live on the Investors & Media section of Fate webcast at fatetherapeutics.com. As a reminder, today’s call is being recorded. I would now like to introduce Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. You may begin sir. Scott Wolchko Thank you. Good afternoon and thanks everyone for joining us for the Fate Therapeutics first quarter 2018 financial results call. Shortly after 4 PM Eastern Time today, we issued a pr
Show less
Read more
Impact Snapshot
Event Time:
FATE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FATE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FATE alerts
High impacting Fate Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FATE
News
- Fate Therapeutics, Inc. (NASDAQ: FATE) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $7.00 price target on the stock.MarketBeat
- Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual MeetingGlobeNewswire
- Fate Therapeutics, Inc. (NASDAQ: FATE) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.MarketBeat
- Fate Therapeutics (FATE) Surges 86.4% YTD on Pipeline Progress [Yahoo! Finance]Yahoo! Finance
FATE
Earnings
- 2/26/24 - Beat
FATE
Sec Filings
- 4/18/24 - Form S-3
- 4/16/24 - Form PRE
- 3/25/24 - Form 4
- FATE's page on the SEC website